Kailera Therapeutics, Inc. Common Stock KLRA
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-07T07:14:16.980Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-06T23:22:59.500925509Z
FundamentalsAlpha Vantage · ready · quarter 2026-09-30 · fetched 2026-11-07T07:14:17.082674+00:00
Kailera Therapeutics, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | ||||||
| 25Δ | 10.53 | 308.9% | 32.9% | |||
| 30Δ | 11.44 | 266.6% | 26.6% | |||
| 35Δ | 12.35 | 224.3% | 20.3% | |||
| 40Δ | 12.98 | 209.1% | 17.2% | |||
| 45Δ | 14.85 | 177.9% | 21.1% | 13.55 | 199.3% | 14.7% |
| 50Δ | 14.30 | 161.2% | 17.4% | 14.12 | 189.5% | 12.2% |
| 55Δ | 13.75 | 144.4% | 13.6% | 14.69 | 179.7% | 9.7% |
| 60Δ | 13.19 | 127.7% | 9.9% | 15.49 | 179.8% | 7.9% |
| 65Δ | 12.64 | 110.9% | 6.1% | 16.57 | 191.5% | 6.9% |
| 70Δ | 17.97 | 210.4% | 6.1% | |||
| 75Δ | 22.42 | 283.9% | 6.1% | |||
| 80Δ | ||||||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 10.53
- IV
- 308.9%
- B/E move
- 32.9%
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 11.44
- IV
- 266.6%
- B/E move
- 26.6%
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 12.35
- IV
- 224.3%
- B/E move
- 20.3%
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 12.98
- IV
- 209.1%
- B/E move
- 17.2%
45Δ
- Pseudo strike
- 14.85
- IV
- 177.9%
- B/E move
- 21.1%
- Pseudo strike
- 13.55
- IV
- 199.3%
- B/E move
- 14.7%
50Δ
- Pseudo strike
- 14.30
- IV
- 161.2%
- B/E move
- 17.4%
- Pseudo strike
- 14.12
- IV
- 189.5%
- B/E move
- 12.2%
55Δ
- Pseudo strike
- 13.75
- IV
- 144.4%
- B/E move
- 13.6%
- Pseudo strike
- 14.69
- IV
- 179.7%
- B/E move
- 9.7%
60Δ
- Pseudo strike
- 13.19
- IV
- 127.7%
- B/E move
- 9.9%
- Pseudo strike
- 15.49
- IV
- 179.8%
- B/E move
- 7.9%
65Δ
- Pseudo strike
- 12.64
- IV
- 110.9%
- B/E move
- 6.1%
- Pseudo strike
- 16.57
- IV
- 191.5%
- B/E move
- 6.9%
70Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 17.97
- IV
- 210.4%
- B/E move
- 6.1%
75Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 22.42
- IV
- 283.9%
- B/E move
- 6.1%
80Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
Options history
Table
| Date | IV (%) |
|---|---|
| 101.87% | |
| 121.04% | |
| 120.32% | |
| 118.83% | |
| 121.49% | |
| 124.08% | |
| 117.08% | |
| 121.68% | |
| 119.91% | |
| 117.21% |
Biotechnology
KOD
Kodiak Sciences Inc., a clinical-stage biopharmaceutical company, is dedicated to researching, developing, and marketing therapies to treat retinal diseases in the United States…
More →KPTI
Karyopharm Therapeutics Inc., a pharmaceutical company, is dedicated to the discovery, development and commercialization of various drugs directed against nuclear export and…
More →KROS
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development and commercialization of novel treatments for patients suffering from…
More →KRRO
Korro Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent…
More →KRYS
Description unavailable
More →KURA
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops drugs for the treatment of cancer in the United States. The company is headquartered in San Diego,…
More →